Mountain Group Capital

Mountain Group News

Latest News


Investment initially to support innovative treatment of Parkinson’s disease

Nashville, Tenn. – June 28, 2018 – Appello Pharmaceuticals, Inc. (“Appello” or “Company”) today announced the completion of a $10.5 million Series A financing led by Deerfield Management and Mountain Group Partners (“MGP”). This initial investment will support the development of novel positive allosteric modulators (“PAMs”) of the metabotropic glutamate receptor subtype 4 (“mGlu4”) as an innovative new treatment for Parkinson’s disease. An estimated 1 million Americans have Parkinson’s disease,…

Research Team Presents Promising Preliminary Results from TBI Study Using Myomo’s MyoPro

Collaborative clinical trial, funded by U.S. Department of Defense, examines the use of a myoelectric arm orthosis to improve arm functionality in traumatic brain injury patients

Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

May 31, 2018 Primary and Secondary Endpoints Met in 6-month Trial Patients Treated with CLS-TA Achieved Comparable Vision Improvement With Fewer Treatments ALPHARETTA, Ga., May 31, 2018 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced positive topline results from its Phase 2 clinical trial (“TYBEE”) evaluating suprachoroidal CLS-TA used with intravitreally…

Anthem, Inc. to Acquire Aspire Health

May 23, 2018 07:00 AM Eastern Daylight Time INDIANAPOLIS–(BUSINESS WIRE)–Anthem, Inc. (NYSE:ANTM) today announced that the company has entered into an agreement to acquire Aspire Health, the nation’s largest non-hospice, community-based palliative care provider. “Anthem is focused on enhancing our ability to offer innovative, integrated clinical care models that can improve the quality of healthcare and deliver better outcomes,” said Gail K. Boudreaux, President and CEO, Anthem. “Aspire Health shares…

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

RESEARCH TRIANGLE PARK, N.C., April 16, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with Tagrisso® (osimertinib) in people with EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC). AstraZeneca (LON: AZN) is providing Tagrisso for this trial under a non-exclusive clinical trial collaboration agreement. “G1T38 inhibits tumor cell…

Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma

New consensus recommendations include test class result to guide risk-appropriate surveillance plans

Friendswood, Texas – March 26 – Castle Biosciences, Inc., today announced that the National Comprehensive Cancer Network (NCCN) has included the DecisionDx®-UM gene expression profile (GEP) test class results in their new clinical practice guidelines for uveal melanoma. These recommendations, released on March 15, 2018, are the first-ever NCCN guidelines for uveal melanoma, and their publication is an important milestone in the care of patients with this rare eye cancer….

G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Bene ts in Patients with Small Cell Lung Cancer

Statistically signi cant results highlight bene t of trilaciclib in several prospectively-de ned parameters, including: Grade 4 neutropenia, G-CSF usage, and chemotherapy dose reductions and delays Clinically meaningful data favoring trilaciclib versus placebo, including: febrile neutropenia, Grade 3/4 anemia, and red blood cell transfusions Management to host webcast and conference call today at 8 a.m. EST RESEARCH TRIANGLE PARK, N.C., March 05, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX),…

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis

Primary Endpoint Achieved – Statistically Significant Improvement in Proportion of Patients Gaining 15 or More Letters in Visual Acuity All Key Secondary Endpoints Achieved

ALPHARETTA, Ga., March 05, 2018 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS- TA in patients with macular edema associated with non-infectious uveitis. Suprachoroidal CLS-TA is Clearside’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via…

Shell Takes a Major Stake in US Solar Developer Silicon Ranch

Shell seeks to expand its global New Energies footprint by acquiring a 44 percent interest in the Nashville-based solar company.

International energy giant Shell has signed a deal to become the largest shareholder of U.S. solar project developer, owner and operator Silicon Ranch Corporation. Under the agreement announced today, Shell will acquire a 43.83 percent interest in Nashville-based Silicon Ranch from Partners Group, a global private markets investment manager. The deal is valued at up to $217 million in cash, based on Silicon Ranch’s performance. Shell has the ability to…

Shell Acquires Interest in Silicon Ranch Corporation

Platform investment aligns Shell with best-in-class U.S. developer, owner, and operator of solar facilities

NASHVILLE, Tenn., Jan. 15, 2018 /PRNewswire/ — Silicon Ranch Corporation, a leading U.S. developer, owner, and operator of solar energy plants, announced today that it has signed an agreement to make Shell its largest shareholder. As part of the agreement, Shell will acquire a 43.83% interest in Silicon Ranch from Partners Group, the global private markets investment manager, for up to $217 million in cash based on Silicon Ranch performance, with the possibility to increase…

← Previous Page&mdashNext Page →